Chapter 12
Technology for Drug Safety: Challenges

12.1 Background

In recent years, technology has become an increasingly important part of healthcare. The use of technology in healthcare has the potential to improve patient outcomes, reduce healthcare costs, and enhance the quality of care provided. One area where technology has shown promise is in addressing drug-related problems [1–22]. These problems include adverse drug reactions, drug interactions, medication errors, and non-adherence to medication regimens. Technology can also be used to address drug abuse and misuse, which is a growing problem around the world. The misuse of prescription drugs, opioids, and other controlled substances has led to a significant increase in drug-related deaths and hospitalizations. Technology can help to detect and prevent drug abuse and misuse by providing healthcare providers with tools to monitor and track patient medication use. Counterfeit and substandard medications are another significant problem in healthcare, particularly in low- and middle-income countries. Counterfeit medications can be ineffective or even harmful, leading to adverse health outcomes and increased healthcare costs. Technology can be used to track and trace medications, providing patients and healthcare providers with assurance that the medications they are using are genuine and safe. Antimicrobial resistance is a growing public health threat that is projected to cause millions of deaths worldwide in the coming years. Antimicrobial stewardship, which involves the appropriate use of antibiotics and other antimicrobial medications, is critical to address this problem. Technology can be used to monitor and track antimicrobial use, detect and prevent antimicrobial resistance, and improve the effectiveness of antimicrobial stewardship programs. While the use of technology in healthcare has shown promise in addressing drug-related problems, drug abuse and misuse, counterfeit medications, and antimicrobial stewardship, there are several challenges that need to be addressed. These challenges include limited adoption of technology, limited resources, complexity of data integration, limited

Y. M. Al-Worafi, *Technology for Drug Safety*, Health Informatics,
https://doi.org/10.1007/978-3-031-34268-4_12

expertise, limited interoperability, privacy concerns, limited scalability, complexity of antimicrobial resistance, resistance to change, limited evidence of effectiveness, limited data availability, integration with clinical workflows, limited education and training, limited patient engagement, limited standardization, legal and regulatory barriers, limited access to technology, and limited collaboration between stakeholders problems [1–22].

12.1.1 Pharmacovigilance

Pharmacovigilance is the science of monitoring, assessing, and preventing adverse effects of medicines. Technology can play an essential role in pharmacovigilance by automating the collection, processing, and analysis of adverse drug reaction (ADR) reports. Electronic health records (EHRs), social media, and mobile health applications are examples of technologies that can be used to collect data on ADRs. Machine learning algorithms can be used to analyze this data to identify potential safety issues and trends. Blockchain technology can help ensure the integrity and security of pharmacovigilance data, as well as enhance transparency and collaboration between stakeholders [1, 2].

12.1.2 ADRs Reporting

Reporting of ADRs is critical to pharmacovigilance. However, underreporting of ADRs is a major problem. Technology can be used to improve the reporting of ADRs by providing healthcare providers with user-friendly reporting tools. Mobile health applications can be used to enable patients to report ADRs directly to regulatory agencies. Additionally, natural language processing (NLP) technology can be used to extract and analyze ADRs from unstructured data sources, such as social media [1, 2].

12.2 Medication Errors

Medication errors are a significant cause of morbidity and mortality in healthcare. Technology can be used to reduce the incidence of medication errors by providing decision support tools for healthcare providers, such as computerized physician order entry (CPOE) systems, clinical decision support systems (CDSS), and barcode medication administration (BCMA) systems. These systems can help prevent medication errors by providing alerts and warnings when there is a potential for drug interactions, incorrect dosages, or other errors. Additionally, technology can be used to report medication errors, enabling healthcare providers to learn from errors and improve patient safety [1, 2].

12.2.1 Drug-Related Problems (DRPs)

DRPs, such as non-adherence to medication regimens, drug interactions, and adverse drug reactions, are a significant problem in healthcare. Technology can be used to address DRPs by providing decision support tools for healthcare providers, such as CDSS and medication reconciliation tools. Additionally, technology can be used to monitor and track patient medication use, enabling healthcare providers to detect and prevent DRPs [1, 2].

12.2.2 Drug Abuse and Misuse

Drug abuse and misuse are growing problems around the world. Technology can be used to detect and prevent drug abuse and misuse by providing healthcare providers with tools to monitor and track patient medication use. Prescription drug monitoring programs (PDMPs) are an example of technology that can be used to monitor and track controlled substance prescriptions. Additionally, mobile health applications can be used to enable patients to track their medication use and receive alerts when it is time to take their medication [1, 2].

12.2.3 Counterfeit and Substandard Medications

Counterfeit and substandard medications are a significant problem in healthcare, particularly in low- and middle-income countries. Technology can be used to track and trace medications, providing patients and healthcare providers with assurance that the medications they are using are genuine and safe. Technologies such as blockchain can be used to provide a tamper-proof record of the supply chain for medications. Additionally, mobile health applications can be used to enable patients to verify the authenticity of their medications [1, 2].

12.2.4 Antimicrobial Stewardship

Antimicrobial stewardship involves the appropriate use of antibiotics and other antimicrobial medications to prevent the development of antimicrobial resistance. Technology can be used to monitor and track antimicrobial use, detect and prevent antimicrobial resistance, and improve the effectiveness of antimicrobial stewardship programs. CDSS can be used to provide healthcare providers with guidance on the appropriate use of antimicrobial medications. Additionally, electronic antimicrobial stewardship tools can be used to track and analyze antimicrobial use data and provide feedback to healthcare providers [1, 2].

12.3 Technology for Drug Safety: Challenges

There are many challenges as following [1–31]:

12.3.1 Technology for Drug Development: Challenges

Technology has revolutionized drug development, making it faster, more accurate, and more efficient than ever before. However, there are still several challenges that researchers face when using technology for drug development. Here are some of the key challenges:

1. Data management: The sheer amount of data generated during drug development is enormous and managing this data can be challenging. Scientists need to be able to organize and analyze large datasets, which requires sophisticated data management tools and expertise.
2. Computational power: As drug development becomes increasingly data-driven, computational power becomes a limiting factor. Scientists need access to high-performance computing resources to run complex simulations and analyze large datasets.
3. Complexity of biology: Biological systems are incredibly complex and understanding how drugs interact with them can be challenging. Researchers need to be able to simulate the behavior of molecules and understand how they interact with cells and tissues, which requires advanced computational tools and expertise.
4. Integration with experimental data: While technology can provide valuable insights into drug development, it is still essential to validate these findings with experimental data. Integrating computational and experimental data can be challenging, as the two often use different types of data and require different analysis techniques.
5. Regulatory hurdles: Drug development is a highly regulated industry and bringing a new drug to market can be a complex and time-consuming process. Technology can help streamline the drug development process, but it must still comply with strict regulatory requirements.
6. Predictive accuracy: Developing drugs requires accurate predictions of their effectiveness and potential side effects. However, the accuracy of these predictions can be limited by the availability and quality of data, as well as the limitations of computational models. Improving the accuracy of predictive models requires ongoing research and development.
7. Interdisciplinary collaboration: Drug development requires collaboration between experts from different disciplines, such as biologists, chemists, and data scientists. Effective collaboration requires clear communication, shared goals, and an understanding of each other's expertise. Achieving this level of

collaboration can be challenging, as each discipline often has its own jargon and research culture.

8. Data privacy and security: Drug development relies on the collection and analysis of sensitive patient data, such as genetic information and medical records. Ensuring the privacy and security of this data is critical, as breaches can compromise patient safety and undermine public trust.
9. Cost: The cost of developing a new drug is high, and technology can help reduce costs by streamlining the drug development process. However, investing in technology and hiring skilled personnel to manage it can also be expensive. Balancing the cost of technology with the potential benefits it provides can be a challenge for drug development organizations.
10. Ethical considerations: Developing drugs raises a number of ethical considerations, such as the use of animal models and the potential for unintended consequences. Technology can help mitigate some of these concerns, such as by providing alternatives to animal testing. However, the ethical implications of using technology in drug development must be carefully considered and addressed.
11. Reproducibility: The reproducibility of scientific results is a critical issue in drug development. Advances in technology have led to an increase in the complexity of experimental methods, which can make it challenging to reproduce results across different labs. Researchers need to ensure that their methods are well-documented, standardized, and validated to ensure that their findings can be reproduced.
12. Bias: The use of technology can introduce bias into drug development, such as in the selection of data or the choice of algorithms. Researchers need to be aware of these biases and take steps to mitigate them, such as through the use of diverse datasets and algorithmic transparency.
13. Accessibility: Access to technology can be a barrier to drug development, particularly for researchers in resource-limited settings. Improving access to technology requires investment in infrastructure, training, and support, which can be challenging to implement.
14. Time constraints: Drug development is a time-sensitive process, and delays can be costly in terms of both resources and patient outcomes. Researchers need to balance the need for thoroughness and accuracy with the need for speed, which can be challenging.
15. Integration with clinical trials: Ultimately, the success of drug development depends on the results of clinical trials. Integrating technology with clinical trials can be challenging, as it requires collaboration between researchers, clinicians, and patients. Ensuring that technology is effectively integrated with clinical trials requires ongoing communication and coordination.

In conclusion, technology has the potential to revolutionize drug development, but it is not without its challenges. Researchers need to be aware of these challenges and work to overcome them through collaboration, innovation, and ongoing investment in research and development.

12.3.2 Technology for Pharmacovigilance and Adverse Drug Reactions (ADRs) Reporting: Challenges

Pharmacovigilance is the science of detecting, assessing, and preventing adverse effects or any other drug-related problems. Technology can play a significant role in pharmacovigilance by automating adverse drug reaction (ADR) reporting and providing tools for data analysis. However, there are still several challenges that need to be addressed. Here are some of the key challenges:

1. Data quality: The quality of data is critical to effective pharmacovigilance. Data must be accurate, complete, and reliable to ensure that adverse events are detected and reported promptly. However, there can be inconsistencies in the way that ADR data is reported, leading to errors and inaccuracies.
2. Integration with existing systems: Pharmacovigilance requires integration with multiple systems, including electronic health records, clinical trial databases, and regulatory databases. Integrating these systems can be challenging, as they may use different data formats and require different analysis techniques.
3. Signal detection: Detecting signals of potential ADRs is a critical part of pharmacovigilance. However, this can be challenging, as the signal-to-noise ratio can be low, and there may be many confounding factors that make it difficult to identify a specific ADR.
4. Data privacy and security: Adverse event data contains sensitive patient information and ensuring the privacy and security of this data is critical. Breaches can compromise patient safety and undermine public trust.
5. Regulatory compliance: Pharmacovigilance is a highly regulated industry, and compliance with regulatory requirements is critical. Automating ADR reporting requires compliance with regulatory requirements, such as the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) guidelines.
6. Interpretation of data: Data analysis is a critical component of pharmacovigilance. However, interpreting data can be challenging, particularly when dealing with large datasets. Researchers need to be able to identify meaningful patterns and trends while avoiding false positives.
7. Capacity building: The implementation of technology for pharmacovigilance requires investment in infrastructure, training, and support. Building the capacity for effective pharmacovigilance requires investment in these areas, which can be challenging in resource-limited settings.
8. Bias and noise reduction: The use of technology for ADR reporting and analysis can introduce bias and noise into the data, which can affect the accuracy of signal detection. Researchers need to ensure that their algorithms are unbiased and that they can differentiate between true signals and noise.
9. Lack of standardization: There is a lack of standardization in ADR reporting, which can make it challenging to compare data across different sources. To overcome this challenge, researchers need to ensure that they are using standard terminology, coding, and reporting procedures.

10. Cultural barriers: Cultural factors can affect ADR reporting and pharmacovigilance practices. In some cultures, there may be a reluctance to report adverse events, which can lead to underreporting. Researchers need to be aware of these cultural barriers and work to address them to ensure that all adverse events are reported.
11. Resource limitations: The use of technology for pharmacovigilance can be costly, which can be a barrier to adoption, particularly in resource-limited settings. Researchers and regulators need to balance the potential benefits of technology with the cost of implementation.
12. Misuse of technology: Technology can be misused, leading to errors and inaccuracies in ADR reporting and analysis. Researchers need to ensure that their algorithms are being used correctly and that they are not being misused to produce false results.
13. Lack of transparency: Lack of transparency in ADR reporting can undermine public trust and confidence in the system. Researchers need to ensure that their algorithms are transparent and that they can be audited and validated to ensure accuracy and reliability.
14. User experience: The user experience of technology used for ADR reporting and pharmacovigilance needs to be intuitive and user-friendly to encourage healthcare professionals to report adverse events. A cumbersome or complicated user interface can discourage reporting, which can lead to underreporting of ADRs.
15. Interoperability: The interoperability of different systems used for ADR reporting and pharmacovigilance is critical to ensure that data can be shared and analyzed effectively. However, interoperability can be challenging when systems use different data formats or are not designed to communicate with each other.
16. Data analytics expertise: Effective ADR reporting and analysis require data analytics expertise to identify patterns and trends in the data. However, there is a shortage of data analytics expertise in some healthcare systems, which can limit the effectiveness of technology in pharmacovigilance.
17. Real-time reporting: Real-time reporting of adverse events can help healthcare professionals to respond quickly to potential safety issues. However, real-time reporting can be challenging, as it requires automated data capture and processing, as well as real-time monitoring of the data.
18. Volume of data: The volume of data generated by ADR reporting systems can be overwhelming, making it difficult to identify and analyze signals of potential safety issues. Researchers need to be able to process large volumes of data quickly and efficiently to identify meaningful signals.
19. Ethical considerations: The use of technology for pharmacovigilance raises ethical considerations related to patient privacy, data sharing, and data ownership. Researchers and regulators need to ensure that ethical considerations are addressed in the development and implementation of technology for ADR reporting and analysis.

Overall, while technology has the potential to improve pharmacovigilance and ADR reporting, there are still several challenges that need to be addressed. Overcoming these challenges will require ongoing investment in research and development, collaboration between industry and regulatory bodies, and a commitment to patient safety.

12.3.3 Technology for Medication Errors and Its Reporting: Challenges

Here are some challenges related to the use of technology for medication error detection, prevention, and reporting:

1. Complexity of medication use: Medication use is a complex process that involves many steps, from prescribing to dispensing to administration. The use of technology for medication error detection and prevention needs to account for this complexity and ensure that all steps in the process are considered.
2. Integration with existing systems: The use of technology for medication error detection and prevention needs to integrate with existing electronic health record (EHR) systems and medication ordering systems. This can be challenging when different systems use different data formats or are not designed to communicate with each other.
3. Data quality: The accuracy and completeness of data are essential for effective medication error detection and prevention. However, the quality of data can be variable, depending on the source of the data and the quality of data entry.
4. User adoption: The success of technology for medication error detection and prevention depends on user adoption, including healthcare professionals who use the system and patients who interact with the system. User adoption can be challenging if the technology is difficult to use or if users perceive it as burdensome.
5. Alert fatigue: The use of technology for medication error detection and prevention can generate alerts, which can lead to alert fatigue if there are too many alerts or if the alerts are not relevant to the user. Alert fatigue can reduce the effectiveness of the technology in preventing medication errors.
6. Cost: The implementation and maintenance of technology for medication error detection and prevention can be costly, which can be a barrier to adoption, particularly in resource-limited settings.
7. Data privacy and security: The use of technology for medication error detection and prevention raises concerns about data privacy and security. Healthcare systems need to ensure that patient data is protected and that the technology complies with regulatory requirements related to data privacy and security.
8. Bias and variability: The use of technology for medication error detection and prevention can introduce bias and variability into the data, which can affect the accuracy of error detection. Researchers need to ensure that their algorithms are unbiased and that they can differentiate between true errors and noise.

9. Over-reliance on technology: Over-reliance on technology can lead to complacency and a reduction in human oversight, which can increase the risk of medication errors. Healthcare professionals need to be trained to use technology as a tool to support their work, rather than relying on it entirely.
10. Data standardization: The use of technology for medication error detection and prevention relies on standardized data. However, data standardization can be challenging, as different healthcare systems use different terminologies and classifications.
11. System interoperability: The interoperability of different systems used for medication error detection and prevention is essential to ensure that data can be shared and analyzed effectively. However, interoperability can be challenging when systems use different data formats or are not designed to communicate with each other.
12. Staff training: The implementation of technology for medication error detection and prevention requires staff training to ensure that healthcare professionals can use the technology effectively. However, staff training can be challenging if healthcare systems are already stretched thin, and there is limited time available for training.
13. Patient engagement: Patient engagement is essential for effective medication error detection and prevention. However, patients may be hesitant to engage with technology, particularly if they perceive it as intrusive or burdensome.
14. Ethical considerations: The use of technology for medication error detection and prevention raises ethical considerations related to patient privacy, data sharing, and data ownership. Healthcare systems need to ensure that ethical considerations are addressed in the development and implementation of technology for medication error detection and prevention.
15. Regulatory compliance: The use of technology for medication error detection and prevention needs to comply with regulatory requirements related to patient safety and data privacy. Healthcare systems need to ensure that their technology complies with relevant regulations and standards.
16. Limited access to technology: In some healthcare settings, access to technology may be limited, particularly in resource-limited settings or rural areas. This can be a significant barrier to the implementation and use of technology for medication error detection and prevention.
17. Variability in medication processes: Medication processes can vary between healthcare systems and settings. This can make it challenging to develop technology solutions that can be widely adopted and effective across different settings.
18. Resistance to change: The implementation of technology for medication error detection and prevention may face resistance from healthcare professionals who may be hesitant to change their established practices or may perceive the technology as an additional burden.
19. Reliance on historical data: The use of technology for medication error detection and prevention relies on the historical data. However, historical data may not always be an accurate reflection of current medication use, particularly if

there have been recent changes in healthcare practices or medication regulations.
20. Need for continuous improvement: The use of technology for medication error detection and prevention needs to be continuously evaluated and improved to ensure that it remains effective and up-to-date with changes in medication practices and regulations.
21. Language barriers: In multilingual healthcare settings, language barriers can be a significant challenge for the use of technology for medication error detection and prevention. Healthcare systems need to ensure that their technology can support different languages and that language barriers are not a barrier to effective medication use.

In conclusion, the use of technology for medication error detection, prevention, and reporting has the potential to improve patient safety. However, several challenges need to be addressed, including limited access to technology, variability in medication processes, resistance to change, reliance on historical data, the need for continuous improvement, and language barriers. Healthcare systems need to address these challenges to ensure that their technology is effective in preventing medication errors and improving patient outcomes.

12.4 Technology for Drug-Related Problems (DRPs): Challenges

12.4.1 Technology for Drug-Related Problems (DRPs) and Therapy-Related Problems: Challenges

Technology has the potential to significantly improve the management of drug-related problems (DRPs) and therapy-related problems, but there are also a number of challenges that need to be addressed in order to maximize the benefits of technology in this area. Some of the key challenges include:

1. Data integration: There are often multiple sources of data involved in managing DRPs and therapy-related problems, including electronic health records, pharmacy systems, and patient-generated data. Integrating these different data sources can be a major challenge, especially when different systems use different data formats or have different levels of data quality.
2. Privacy and security: Patient health data is highly sensitive, and there are strict regulations around its use and sharing. Ensuring that technology solutions for DRPs and therapy-related problems comply with these regulations and maintain patient privacy and security is essential but can be a complex process.
3. User adoption: Technology solutions for DRPs and therapy-related problems need to be easy to use and integrate seamlessly into healthcare workflows in order to be effective. However, healthcare providers may be resistant to adopt-

ing new technologies, particularly if they are perceived as adding extra work or disrupting existing processes.

4. Data analytics: Making sense of the vast amounts of data generated by technology solutions for DRPs and therapy-related problems requires sophisticated data analytics capabilities. However, many healthcare organizations do not have the expertise or resources to develop and maintain these capabilities in-house.
5. Interoperability: In order for technology solutions for DRPs and therapy-related problems to be effective, they need to be able to exchange data with other systems and applications. Ensuring that different technology solutions can interoperate with each other can be a challenge, particularly if they were developed by different vendors or using different data standards.
6. Technical infrastructure: Technology solutions for DRPs and therapy-related problems require robust technical infrastructure, including hardware, software, and networking components. Ensuring that this infrastructure is reliable, secure, and able to handle the volume of data generated by these solutions can be a significant challenge, particularly for smaller healthcare organizations with limited resources.
7. Standardization: In order to ensure interoperability between different technology solutions, it is important to have standardized data formats and protocols. However, developing and implementing these standards can be a complex and time-consuming process, particularly when there are competing standards or multiple stakeholders with different requirements.
8. Quality assurance: Ensuring the quality of technology solutions for DRPs and therapy-related problems is essential to avoid errors or adverse events. However, quality assurance processes can be challenging to implement, particularly when solutions are updated or modified over time.
9. Cost: Developing and implementing technology solutions for DRPs and therapy-related problems can be expensive, particularly for smaller healthcare organizations with limited budgets. Ensuring that these solutions are cost-effective and provide value for money can be a significant challenge.
10. Legal and regulatory issues: There are a number of legal and regulatory issues that need to be addressed when developing and implementing technology solutions for DRPs and therapy-related problems, including issues related to liability, intellectual property, and data privacy. Ensuring compliance with these regulations can be a significant challenge, particularly for organizations operating in multiple jurisdictions or with complex legal and regulatory requirements.
11. Training and education: In order to ensure that healthcare providers are able to effectively use technology solutions for DRPs and therapy-related problems, training and education programs may be necessary. Developing and implementing these programs can be time-consuming and resource-intensive, particularly if healthcare providers have different levels of technology literacy or experience.
12. Patient engagement: Technology solutions for DRPs and therapy-related problems may require active patient engagement in order to be effective. However, ensuring that patients are willing and able to use these solutions can be a chal-

lenge, particularly if they have limited access to technology or are hesitant to share personal health information.
13. Data quality: Ensuring the quality and accuracy of data generated by technology solutions for DRPs and therapy-related problems is essential in order to avoid errors or adverse events. However, maintaining data quality can be a challenge, particularly if data is generated by multiple sources or is entered manually.
14. Scalability: Technology solutions for DRPs and therapy-related problems need to be able to scale up or down as needed to accommodate changes in patient volume or healthcare workflows. Ensuring that these solutions are able to scale effectively can be a challenge, particularly if they rely on complex or proprietary technology.
15. Integration with existing systems: Technology solutions for DRPs and therapy-related problems need to be able to integrate seamlessly with existing healthcare systems and workflows in order to be effective. However, ensuring this integration can be a challenge, particularly if different systems use different data formats or have different levels of data quality.

12.5 Technology for Drug Abuse and Misuse Detection Prevention and Management: Challenges

Technology has the potential to play a significant role in the detection, prevention, and management of drug abuse and misuse. However, there are also a number of challenges that need to be addressed in order to maximize the benefits of technology in this area. Some of the key challenges include:

1. Data privacy and security: Patient health data is highly sensitive, and there are strict regulations around its use and sharing. Ensuring that technology solutions for drug abuse and misuse detection, prevention, and management comply with these regulations and maintain patient privacy and security is essential but can be a complex process.
2. Accuracy and reliability: Technology solutions for drug abuse and misuse detection, prevention, and management need to be accurate and reliable in order to be effective. However, there is a risk of false positives or false negatives, which could lead to inappropriate interventions or missed opportunities for intervention.
3. Integration with existing systems: Technology solutions for drug abuse and misuse detection, prevention, and management need to be able to integrate seamlessly with existing healthcare systems and workflows in order to be effective. However, ensuring this integration can be a challenge, particularly if different systems use different data formats or have different levels of data quality.
4. User adoption: Technology solutions for drug abuse and misuse detection, prevention, and management need to be easy to use and integrate seamlessly into

healthcare workflows in order to be effective. However, healthcare providers may be resistant to adopting new technologies, particularly if they are perceived as adding extra work or disrupting existing processes.

5. Cost: Developing and implementing technology solutions for drug abuse and misuse detection, prevention, and management can be expensive, particularly for smaller healthcare organizations with limited budgets. Ensuring that these solutions are cost-effective and provide value for money can be a significant challenge.
6. Technical infrastructure: Technology solutions for drug abuse and misuse detection, prevention, and management require robust technical infrastructure, including hardware, software, and networking components. Ensuring that this infrastructure is reliable, secure, and able to handle the volume of data generated by these solutions can be a significant challenge, particularly for smaller healthcare organizations with limited resources.
7. Patient engagement: Technology solutions for drug abuse and misuse detection, prevention, and management may require active patient engagement in order to be effective. However, ensuring that patients are willing and able to use these solutions can be a challenge, particularly if they have limited access to technology or are hesitant to share personal health information.
8. Legal and regulatory issues: There are a number of legal and regulatory issues that need to be addressed when developing and implementing technology solutions for drug abuse and misuse detection, prevention, and management, including issues related to liability, intellectual property, and data privacy. Ensuring compliance with these regulations can be a significant challenge, particularly for organizations operating in multiple jurisdictions or with complex legal and regulatory requirements.
9. Data analytics: Making sense of the vast amounts of data generated by technology solutions for drug abuse and misuse detection, prevention, and management requires sophisticated data analytics capabilities. However, many healthcare organizations do not have the expertise or resources to develop and maintain these capabilities in-house.
10. Standardization: In order to ensure interoperability between different technology solutions, it is important to have standardized data formats and protocols. However, developing and implementing these standards can be a complex and time-consuming process, particularly when there are competing standards or multiple stakeholders with different requirements.
11. Stigma and discrimination: Stigma and discrimination are significant barriers to addressing drug abuse and misuse, and technology solutions can inadvertently perpetuate these issues. Ensuring that technology solutions for drug abuse and misuse detection, prevention, and management do not stigmatize or discriminate against individuals with substance use disorders is important but can be a complex process.
12. Cultural and linguistic diversity: Healthcare organizations serve diverse patient populations with varying cultural and linguistic backgrounds. Ensuring that technology solutions for drug abuse and misuse detection, prevention, and man-

agement are culturally and linguistically appropriate can be a challenge, particularly if these solutions rely on complex language or cultural assumptions.

13. Limited interoperability: The lack of interoperability between different technology solutions is a significant challenge in healthcare, and this is particularly true for drug abuse and misuse detection, prevention, and management. Ensuring that these solutions are able to integrate with other healthcare technologies, such as electronic health records, can be a significant challenge.
14. Ethical considerations: There are a number of ethical considerations that need to be taken into account when developing and implementing technology solutions for drug abuse and misuse detection, prevention, and management. These include issues related to consent, privacy, and autonomy, and ensuring that these considerations are addressed can be a significant challenge.
15. Bias and discrimination in algorithms: Machine learning algorithms are increasingly being used in healthcare, but there is a risk that these algorithms may perpetuate bias and discrimination against certain patient populations. Ensuring that algorithms used in drug abuse and misuse detection, prevention, and management are unbiased and do not perpetuate discrimination is important but can be a significant challenge.
16. Limited access to technology: Not all patients have access to the technology required to use drug abuse and misuse detection, prevention, and management solutions. This can be due to a lack of resources, limited digital literacy, or geographic barriers. Ensuring that these solutions are accessible to all patients, regardless of their socioeconomic status or geographic location, can be a significant challenge.
17. Lack of evidence-based solutions: While there is potential for technology to play a significant role in addressing drug abuse and misuse, there is limited evidence on the effectiveness of many technology solutions in this area. Ensuring that technology solutions for drug abuse and misuse detection, prevention, and management are evidence-based and have been rigorously tested can be a significant challenge.
18. Training and support: Healthcare providers and patients may require training and support to effectively use technology solutions for drug abuse and misuse detection, prevention, and management. Ensuring that this training and support is available can be a challenge, particularly for healthcare organizations with limited resources.
19. Systematic implementation: Implementing technology solutions for drug abuse and misuse detection, prevention, and management requires a systematic approach that involves all stakeholders, including patients, healthcare providers, and technology vendors. Ensuring that this approach is followed can be a significant challenge, particularly if there is resistance to change or competing priorities.
20. Sustainability: Technology solutions for drug abuse and misuse detection, prevention, and management require ongoing maintenance and support in order to remain effective. Ensuring that these solutions are sustainable over the long term, both in terms of funding and technical infrastructure, can be a significant challenge, particularly for smaller healthcare organizations with limited resources.

12.6 Technology for Counterfeit and Substandard Medications: Challenges

1. Lack of uniform regulations: There are no uniform global regulations for detecting and preventing counterfeit and substandard medications. Different countries have their own regulations and guidelines, making it difficult to create a consistent approach to detecting and preventing counterfeit and substandard medications.
2. Difficulty in tracking medications: It is challenging to track the distribution of medications throughout the supply chain, which can make it difficult to detect and prevent counterfeit and substandard medications. Tracking medications requires the use of various technologies such as radio-frequency identification (RFID) tags and blockchain, which can be expensive and not widely adopted.
3. Limited resources for enforcement: Many regulatory agencies have limited resources to monitor the distribution of medications and detect counterfeit and substandard products. This can lead to a lack of enforcement and create opportunities for counterfeiters to continue their activities.
4. Limited adoption of technology: Many pharmaceutical companies and regulatory agencies have been slow to adopt new technologies, such as blockchain and artificial intelligence, to detect and prevent counterfeit and substandard medications. This slow adoption can lead to a lack of innovation and a continued reliance on outdated technologies.
5. Cost: Implementing technology to detect and prevent counterfeit and substandard medications can be expensive, particularly for smaller pharmaceutical companies and regulatory agencies. The cost of implementing new technologies can be a barrier to adoption, especially if there is no immediate return on investment.
6. Privacy concerns: The use of technology to track medications raises concerns about privacy and data security. Patient information must be protected to prevent unauthorized access to sensitive data.
7. Limited expertise: Many regulatory agencies and pharmaceutical companies lack the technical expertise required to implement and maintain new technologies for detecting and preventing counterfeit and substandard medications. This can lead to a reliance on third-party vendors, which can be costly.
8. Limited international collaboration: Counterfeit and substandard medications are a global problem that requires international collaboration to detect and prevent. However, there is limited international collaboration, making it difficult to create a coordinated approach to detecting and preventing counterfeit and substandard medications.
9. Cultural and linguistic diversity: Healthcare organizations serve diverse patient populations with varying cultural and linguistic backgrounds. Ensuring that technology solutions for detecting and preventing counterfeit and substandard medications are culturally and linguistically appropriate can be a challenge, particularly if these solutions rely on complex language or cultural assumptions.

10. Limited interoperability: The lack of interoperability between different technology solutions is a significant challenge in healthcare, and this is particularly true for detecting and preventing counterfeit and substandard medications. Ensuring that these solutions are able to integrate with other healthcare technologies, such as electronic health records, can be a significant challenge.
11. Lack of standardization: There is a lack of standardization for the data formats and structures used in technology solutions for detecting and preventing counterfeit and substandard medications. This can make it difficult to share information and collaborate across different healthcare organizations and technology solutions.
12. Limited awareness: Healthcare providers, patients, and regulatory agencies may not be aware of the risks associated with counterfeit and substandard medications or the technology solutions available to detect and prevent them. Raising awareness and educating stakeholders can be a significant challenge, particularly in regions with limited access to healthcare and technology resources.
13. Complexity of the supply chain: The pharmaceutical supply chain is complex and involves multiple parties, including manufacturers, distributors, wholesalers, and retailers. This complexity can make it difficult to track medications and detect counterfeit and substandard products.
14. Inadequate testing: Many technology solutions for detecting and preventing counterfeit and substandard medications have not been rigorously tested or evaluated, leading to uncertainty about their effectiveness.
15. Limited scalability: Technology solutions for detecting and preventing counterfeit and substandard medications may work well in small-scale pilots but scaling these solutions to larger populations can be challenging. Ensuring that technology solutions are scalable and can be implemented across different regions and healthcare organizations is critical to their success.
16. Adapting to new methods: As technology advances, new methods of counterfeiting and substandard medication production emerge, requiring constant adaptation and innovation in technology solutions. Keeping up with these advancements can be a significant challenge.
17. Limited access to technology: In many parts of the world, access to technology and the internet is limited, making it difficult to implement technology solutions for detecting and preventing counterfeit and substandard medications.
18. Limited capacity for data analysis: Collecting and analyzing data on medication distribution and usage is critical for detecting and preventing counterfeit and substandard medications. However, many healthcare organizations and regulatory agencies have limited capacity for data analysis, which can hinder efforts to detect and prevent counterfeit and substandard medications.
19. Legal and regulatory barriers: Legal and regulatory barriers can prevent the adoption and implementation of technology solutions for detecting and preventing counterfeit and substandard medications. These barriers may include intellectual property rights, data privacy laws, and regulations on the use of certain technologies.
20. Collaboration between stakeholders: The fight against counterfeit and substandard medications requires collaboration between various stakeholders, includ-

ing healthcare providers, pharmaceutical companies, regulatory agencies, and technology companies. Building trust and collaboration between these stakeholders can be a significant challenge, particularly in regions with a history of mistrust or corruption.

12.7 Technology for Antimicrobial Stewardship: Challenges

1. Limited adoption of technology: Many healthcare organizations and providers have been slow to adopt technology solutions for antimicrobial stewardship, such as electronic health records and decision support tools. This slow adoption can lead to a lack of innovation and a continued reliance on outdated technologies.
2. Limited resources: Implementing technology solutions for antimicrobial stewardship can be expensive, particularly for smaller healthcare organizations and providers. The cost of implementing new technologies can be a barrier to adoption, especially if there is no immediate return on investment.
3. Complexity of data integration: Antimicrobial stewardship requires the integration of data from various sources, including laboratory results, clinical notes, and patient histories. Integrating these data sources can be complex, particularly if the data is stored in different systems or formats.
4. Limited expertise: Many healthcare providers and organizations lack the technical expertise required to implement and maintain new technologies for antimicrobial stewardship. This can lead to a reliance on third-party vendors, which can be costly.
5. Limited interoperability: The lack of interoperability between different technology solutions is a significant challenge in healthcare, and this is particularly true for antimicrobial stewardship. Ensuring that these solutions are able to integrate with other healthcare technologies, such as electronic health records, can be a significant challenge.
6. Privacy concerns: The use of technology to track and manage antimicrobial use raises concerns about privacy and data security. Patient information must be protected to prevent unauthorized access to sensitive data.
7. Limited scalability: Technology solutions for antimicrobial stewardship may work well in small-scale pilots but scaling these solutions to larger populations can be challenging. Ensuring that technology solutions are scalable and can be implemented across different regions and healthcare organizations is critical to their success.
8. Complexity of antimicrobial resistance: Antimicrobial resistance is a complex and evolving problem that requires constant adaptation and innovation in technology solutions. Keeping up with these advancements can be a significant challenge.
9. Resistance to change: Healthcare providers and organizations may resist changes to existing practices and workflows, particularly if they perceive technology solutions to be cumbersome or difficult to use.
10. Limited evidence of effectiveness: Many technology solutions for antimicrobial stewardship have not been rigorously tested or evaluated, leading to uncertainty about their effectiveness.

11. Limited data availability: Collecting and analyzing data on antimicrobial use and resistance is critical for effective antimicrobial stewardship. However, in many regions, there is limited data availability, making it challenging to implement technology solutions that rely on data analysis.
12. Integration with clinical workflows: Technology solutions for antimicrobial stewardship must be integrated into existing clinical workflows to be effective. However, this integration can be complex and require significant changes to existing processes, which can be difficult to implement.
13. Limited education and training: Healthcare providers and organizations may lack the education and training necessary to effectively use technology solutions for antimicrobial stewardship. Ensuring that healthcare providers are adequately trained in the use of these technologies is critical for their success.
14. Limited patient engagement: Antimicrobial stewardship requires the engagement and participation of patients, who must be educated on the appropriate use of antimicrobial medications. However, patient engagement can be challenging, particularly if patients do not have access to information or do not perceive the problem of antimicrobial resistance to be relevant to them.
15. Limited standardization: There is a lack of standardization for the data formats and structures used in technology solutions for antimicrobial stewardship. This can make it difficult to share information and collaborate across different healthcare organizations and technology solutions.
16. Legal and regulatory barriers: Legal and regulatory barriers can prevent the adoption and implementation of technology solutions for antimicrobial stewardship. These barriers may include intellectual property rights, data privacy laws, and regulations on the use of certain technologies.
17. Limited access to technology: In many parts of the world, access to technology and the internet is limited, making it difficult to implement technology solutions for antimicrobial stewardship.
18. Limited collaboration between stakeholders: The fight against antimicrobial resistance requires collaboration between various stakeholders, including healthcare providers, pharmaceutical companies, regulatory agencies, and technology companies. Building trust and collaboration between these stakeholders can be a significant challenge.

12.8 Technology for Self-Medications: Challenges

Self-medication refers to the practice of treating oneself with over-the-counter (OTC) medications without the advice of a healthcare professional. While technology has the potential to facilitate self-medication, there are several challenges that need to be addressed.

1. Lack of regulation: The availability of health-related applications and OTC medications on the internet has increased the risk of self-medication. However, the

lack of regulation and control over these products and services poses a significant challenge.
2. Misleading information: The quality and accuracy of health-related information on the internet are highly variable. There is a risk that individuals may self-diagnose and self-treat based on misleading or incorrect information.
3. Adverse events: Self-medication can lead to adverse events such as allergic reactions, drug interactions, and medication errors. The risk of adverse events is higher in individuals with pre-existing medical conditions and those taking prescription medications.
4. Lack of healthcare professional involvement: Self-medication reduces the role of healthcare professionals in the treatment process, leading to a lack of monitoring and follow-up. This can result in delayed diagnosis and treatment of underlying medical conditions.
5. Data privacy and security: The use of health-related applications and digital health services for self-medication raises concerns regarding the privacy and security of personal health information. The risk of data breaches and misuse of personal health information is a significant challenge.
6. Digital divide: The digital divide refers to the unequal distribution of technology and internet access among populations. Individuals who lack access to technology or have limited digital literacy may be excluded from the benefits of technology-based self-medication.
7. Lack of accountability: Self-medication also poses a challenge in terms of accountability. Individuals may not take responsibility for their health outcomes or may blame technology and OTC medications for adverse events, which can lead to a lack of accountability in the treatment process.

To address these challenges, it is essential to ensure that the regulation and quality control of health-related products and services are improved. Health literacy programs and education initiatives should be implemented to improve individuals' understanding of their health and the risks associated with self-medication. Additionally, healthcare professionals should play a more active role in the self-medication process by providing guidance and monitoring individuals who engage in self-medication. Finally, efforts should be made to ensure the privacy and security of personal health information, and the digital divide should be addressed to ensure that technology-based self-medication is accessible to all.

12.9 Technology for Storage and Disposal of Medications: Challenges

The storage and disposal of medications is an essential aspect of medication safety, and technology can play a crucial role in this process. However, there are several challenges that need to be addressed to ensure that technology is effectively used in the storage and disposal of medications.

1. Access to technology: One of the main challenges is the lack of access to technology, particularly in low-income communities and in rural areas. Many people in these areas may not have access to smartphones or other devices that can be used to track medication storage and disposal.
2. Reliability of technology: Technology is only as reliable as the infrastructure supporting it. Technical issues such as power outages, network connectivity problems, or device malfunctions can disrupt the proper functioning of technology-based storage and disposal systems.
3. Lack of user-friendly technology: Technology-based storage and disposal systems must be user-friendly to encourage their use. Complicated and challenging systems may discourage patients and caregivers from using them, leading to non-adherence to safe medication storage and disposal practices.
4. Integration with healthcare systems: Technology-based storage and disposal systems must integrate with healthcare systems to provide accurate and timely information to healthcare professionals. This requires the development of interoperability standards and the coordination of various stakeholders involved in the medication management process.
5. Data privacy and security: Technology-based storage and disposal systems may collect personal health information, including medication data and patient health information. This requires strict data privacy and security measures to protect the confidentiality of patient information.
6. Cost: The development and implementation of technology-based storage and disposal systems can be costly. The cost may be a barrier to access for some patients and healthcare providers, particularly in resource-limited settings.
7. Environmental impact: The disposal of medications can have an environmental impact. Technology-based disposal systems must be designed to minimize this impact, such as through proper disposal methods that reduce waste and pollution.

To address these challenges, there needs to be a concerted effort to improve access to technology, particularly in underserved communities. The technology used must be reliable and user-friendly, and integration with healthcare systems should be prioritized. Strict data privacy and security measures must be in place, and cost-effective solutions should be explored. Finally, efforts should be made to develop technology-based disposal systems that minimize environmental impact.

12.10 Technology for Safety of Herbal Medications and Nutraceuticals: Challenges

The use of herbal medications and nutraceuticals is increasing, and technology can play a critical role in ensuring their safety. However, there are several challenges associated with the use of technology in this area as follows:

1. Lack of standardized testing methods: There is a lack of standardized testing methods for herbal medications and nutraceuticals, making it challenging to develop reliable technology-based safety measures.

2. Quality control: Ensuring the quality and purity of herbal medications and nutraceuticals is challenging, as they are often produced in small quantities by non-regulated manufacturers. Technology can help in quality control, but the challenge is to develop reliable and accurate testing methods.
3. Safety testing: There is a lack of safety testing for herbal medications and nutraceuticals, which can lead to adverse reactions or interactions with other medications. Technology can play a role in the safety testing of these products but developing accurate and reliable testing methods is essential.
4. Lack of regulatory oversight: In many countries, there is little or no regulatory oversight of herbal medications and nutraceuticals, making it challenging to develop technology-based safety measures. In the absence of regulatory oversight, the development and implementation of technology-based safety measures may be limited.
5. Limited research: There is limited research on the safety and efficacy of herbal medications and nutraceuticals, making it challenging to develop technology-based safety measures. More research is needed to understand the effects of these products on the body and how they interact with other medications.
6. Public perception: The perception that herbal medications and nutraceuticals are "natural" and therefore safe can be a barrier to the development and implementation of technology-based safety measures. This perception can lead to a lack of demand for these measures and limited funding for their development.
7. Cost: The development and implementation of technology-based safety measures for herbal medications and nutraceuticals can be costly. The cost may be a barrier to access for some patients and healthcare providers.

To address these challenges, there needs to be a concerted effort to standardize testing methods, improve quality control, and increase safety testing. Regulatory oversight must be strengthened, and more research is needed to understand the safety and efficacy of these products. Public perception should also be addressed, and efforts should be made to develop cost-effective solutions for the development and implementation of technology-based safety measures.

12.11 Technology for Vaccines Safety: Challenges

Technology can play a significant role in ensuring the safety of vaccines, particularly in the development, distribution, and monitoring of vaccine safety. However, there are several challenges associated with the use of technology in this area as follows:

1. Development of new vaccine technologies: There is a need for the development of new vaccine technologies that can improve the efficacy and safety of vaccines. New technologies such as mRNA vaccines, while promising, present new challenges in terms of manufacturing, storage, and distribution.
2. Vaccine distribution: The safe and timely distribution of vaccines is critical to their effectiveness. However, many countries lack the necessary infrastructure

to distribute vaccines safely and efficiently. Additionally, some vaccines require ultra-cold storage, which can be challenging in some areas.

3. Adverse event monitoring: The monitoring of adverse events following immunization (AEFIs) is critical in ensuring the safety of vaccines. However, current monitoring systems are often fragmented, making it challenging to identify and track adverse events accurately.
4. Vaccine hesitancy: Vaccine hesitancy is a growing challenge, particularly in developed countries. This hesitancy can be influenced by misinformation and lack of trust in the healthcare system, making it challenging to ensure the uptake of vaccines.
5. Data privacy and security: The collection, storage, and analysis of vaccine safety data can raise concerns about data privacy and security. It is essential to ensure that the technology used to collect and store data is secure and that patient privacy is protected.
6. Vaccine efficacy in different populations: There is a need to ensure that vaccines are effective and safe for different populations, such as pregnant women and people with pre-existing medical conditions. This requires careful monitoring of vaccine safety and efficacy in different populations.
7. Vaccine supply chain: Ensuring the safety of vaccines requires a secure and reliable supply chain. However, vaccine supply chains can be complex, with multiple stakeholders involved, making it challenging to ensure the integrity and safety of vaccines.
8. Another challenge in vaccine safety is the need for a global approach to monitoring and responding to vaccine safety concerns. With the increasing globalization of vaccine manufacturing and distribution, it is crucial to have a coordinated global approach to vaccine safety. This includes standardizing adverse event reporting systems and ensuring that vaccine safety data is shared across countries and regions.
9. Additionally, the rapid development and distribution of vaccines during the COVID-19 pandemic have highlighted the challenges of ensuring vaccine safety in emergency situations. The use of new vaccine technologies, such as mRNA vaccines, has also raised new safety concerns that require careful monitoring and analysis.
10. Furthermore, ensuring the safety of vaccines also requires addressing the issue of vaccine counterfeit and falsification, which can lead to the distribution of substandard or ineffective vaccines. Technology such as blockchain can be used to track and verify the authenticity of vaccines, but implementation at a global level requires cooperation and coordination between stakeholders.
11. Finally, there is a need to ensure equitable access to safe and effective vaccines, particularly in low- and middle-income countries. This requires addressing the challenges of vaccine distribution and supply chain in these countries, as well as addressing the issue of vaccine hesitancy and misinformation.

In conclusion, technology can play a crucial role in ensuring the safety of vaccines, but it is not without its challenges. Addressing these challenges requires a coordinated and global approach, investment in new vaccine technologies, and efforts to strengthen vaccine distribution infrastructure and supply chains.

12.12 Conclusion

In conclusion, the use of technology in various aspects of healthcare, including drug-related problems, drug abuse and misuse, counterfeit medications, and antimicrobial stewardship, has the potential to improve patient outcomes and reduce healthcare costs. However, there are several challenges that need to be addressed, including limited adoption of technology, limited resources, complexity of data integration, limited expertise, limited interoperability, privacy concerns, limited scalability, complexity of antimicrobial resistance, resistance to change, limited evidence of effectiveness, limited data availability, integration with clinical workflows, limited education and training, limited patient engagement, limited standardization, legal and regulatory barriers, limited access to technology, and limited collaboration between stakeholders. Addressing these challenges requires collaboration between various stakeholders, including healthcare providers, pharmaceutical companies, regulatory agencies, and technology companies. Furthermore, there is a need for continued innovation and investment in technology solutions that can address the challenges of drug-related problems, drug abuse and misuse, counterfeit medications, and antimicrobial stewardship. Ultimately, the use of technology must be integrated into existing clinical workflows and must be user-friendly and accessible to all healthcare providers and patients.

References

1. Al-Worafi YM, editor. Drug safety in developing countries: achievements and challenges; 2020.
2. Al-Worafi YM. Technology in medications safety. In: Drug safety in developing countries. Academic Press; 2020. p. 203–12.
3. Al-Worafi YM. Medications safety-related terminology. In: Drug safety in developing countries. Academic Press; 2020. p. 7–19.
4. Al-Worafi YM. Medications registration and marketing: safety-related issues. In: Drug safety in developing countries. Academic Press; 2020. p. 21–8.
5. Al-Worafi YM. Pharmacovigilance. In: Drug safety in developing countries. Academic Press; 2020. p. 29–38.
6. Al-Worafi YM. Adverse drug reactions. In: Drug safety in developing countries. Academic Press; 2020. p. 39–57.
7. Al-Worafi YM. Medication errors. In: Drug safety in developing countries. Academic Press; 2020. p. 105–17.

8. Al-Worafi YM. Drug-related problems. In: Drug safety in developing countries. Academic Press; 2020. p. 59–71.
9. Al-Worafi YM. Self-medication. In: Drug safety in developing countries. Academic Press; 2020. p. 73–86.
10. Al-Worafi YM. Antibiotics safety issues. In: Drug safety in developing countries. Academic Press; 2020. p. 87–103.
11. Al-Worafi YM. Medications safety research issues. In: Drug safety in developing countries. Academic Press; 2020. p. 213–27.
12. Al-Worafi YM. Counterfeit and substandard medications. In: Drug safety in developing countries. Academic Press; 2020. p. 119–26.
13. Al-Worafi YM. Medication abuse and misuse. In: Drug safety in developing countries. Academic Press; 2020. p. 127–35.
14. Al-Worafi YM. Storage and disposal of medications. In: Drug safety in developing countries. Academic Press; 2020. p. 137–42.
15. Al-Worafi YM. Herbal medicines safety issues. In: Drug safety in developing countries. Academic Press; 2020. p. 163–78.
16. Al-Worafi YM. Evidence-based medications safety practice. In: Drug safety in developing countries. Academic Press; 2020. p. 197–201.
17. Al-Worafi YM. Quality indicators for medications safety. In: Drug safety in developing countries. Academic Press; 2020. p. 229–42.
18. Al-Worafi YM. Drug safety: comparison between developing countries. In: Drug safety in developing countries. Academic Press; 2020. p. 603–11.
19. Al-Worafi YM. Drug safety in developing versus developed countries. In: Drug safety in developing countries. Academic Press; 2020. p. 613–5.
20. Battles JB, Keyes MA. Technology and patient safety: a two-edged sword. Biomed Instrum Technol. 2002;36(2):84–8.
21. Huckvale C, Car J, Akiyama M, Jaafar S, Khoja T, Khalid AB, et al. Information technology for patient safety. BMJ Qual Saf. 2010;19(Suppl 2):i25–33.
22. Lu Z. Information technology in pharmacovigilance: benefits, challenges, and future directions from industry perspectives. Drug Healthc Patient Saf. 2009:35–45.
23. Al-Worafi Y. A guide to online pharmacy education: teaching strategies and assessment methods. CRC Press; 2022.
24. Al-Worafi YM, editor. Clinical case studies on medication safety. Academic Press; 2023.
25. Elangovan D, Long CS, Bakrin FS, Tan CS, Goh KW, Hussain Z, et al. Application of blockchain technology in hospital information system. In: Mathematical modeling and soft computing in epidemiology; 2020. p. 231–46.
26. Izahar S, Lean QY, Hameed MA, Murugiah MK, Patel RP, Al-Worafi YM, et al. Content analysis of mobile health applications on diabetes mellitus. Front Endocrinol. 2017;8:318.
27. Loy MJ, Goh KW, Osili N, Ming LC, Dhaliwal JS, Hermansyah A, et al. Features and functionalities of medical mobile applications for the endemic phase of COVID-19: review and content analysis. Prog Microbes Mol Biol. 2022;5(1).
28. Kumaran H, Long CS, Bakrin FS, Tan CS, Goh KW, Al-Worafi YM, et al. Online pharmacies: desirable characteristics and regulations. Drugs Ther Perspect. 2020;36:243–5.
29. Ming LC, Hameed MA, Lee DD, Apidi NA, Lai PSM, Hadi MA, et al. Use of medical mobile applications among hospital pharmacists in Malaysia. Ther Innov Regul Sci. 2016;50(4):419–26.
30. Ming LC, Untong N, Aliudin NA, Osili N, Kifli N, Tan CS, et al. Mobile health apps on COVID-19 launched in the early days of the pandemic: content analysis and review. JMIR Mhealth Uhealth. 2020;8(9):e19796.
31. Ng CZ, Lean YL, Yeoh SF, Lean QY, Lee KS, Suleiman AK, et al. Cold chain time-and temperature-controlled transport of vaccines: a simulated experimental study. Clin Exp Vaccine Res. 2020;9(1):8–14.